Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences CEO Kirkpatrick to become COO after December 14, 2026 annual meeting

Neutral Impact 4 of 5 leadership Written later

Ensysce Biosciences said director Will Chang intends to resign after the next annual meeting, and CEO Dr. Lynn Kirkpatrick will step down as CEO and take the title of Chief Operating Officer right after that meeting. President James Morrisson is set to become CEO at the same time, a change the company had previously reported, which gives shareholders a planned leadership transition.

Key points

  • Annual meeting scheduled for December 14, 2026; Kirkpatrick's title change and Chang's resignation take effect around it, and both would be delayed if the meeting is delayed.
  • James Morrisson, the company's President, will assume the title of Chief Executive Officer immediately after the annual meeting.
  • Kirkpatrick agreed to amend her September 14, 2021 employment offer letter so that taking the COO role will not trigger severance obligations.
  • Kirkpatrick has been CEO since January 2009 and also serves as CEO of EBIR, Inc., in which the company owns 79.2%.

The filing

CompanyEnsysce Biosciences, Inc. (ENSC)
Form8-K, current report
Filed with the SECNov 4, 2026, 12:46 PM ET
Accession number0001493152-26-049906

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.